{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"DLT: any of adverse events (AEs), assessed by Investigator and/Sponsor at any dose, regimen, and judged not to be related to underlying disease/any previous/concomitant medication/concurrent condition during first cycle of study treatment. DLT was confirmed by Safety Monitoring Committee. DLTs: Grade (Gr) greater than/equal to (\\>=) 3 nonhematologic AE with exception of: Single laboratory values out of abnormal range; Gr3 diarrhea persisting less than or equal to \\[\\<=\\] 72 hour (hr); Nausea and vomiting \\<= 72 hr; Transient Gr3 fatigue, local reactions, flu-like symptoms \\<= 72 hr; Gr3 nonrecurrent skin toxicity; Asymptomatic Gr \\>= 3 lipase/amylase elevation. Any Gr \\>= 4 hematologic AE: Gr \\>= 3 febrile neutropenia with Absolute Neutrophil Count (ANC) \\<1000 per cube millimeter and temperature of \\>38.3 Celsius (°C); Gr \\>= 3 thrombocytopenia; Gr4 thrombocytopenia lasting \\>7 days.","groups":[{"description":"Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) until disease progression.","id":"OG000","title":"M3258 10 mg QD"},{"description":"Participants received M3258 at a dose of 10 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG001","title":"M3258 10 mg Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG002","title":"M3258 20 mg Twice Per Week"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT analysis set: all participants who received at least 1 dose of study intervention and meet at least 1 of criteria specified in statistical analysis plan.","reportingStatus":"POSTED","timeFrame":"Day 1 up to Day 28","title":"Part A: Number of Participants With Dose-Limiting Toxicities (DLTs) as Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0","type":"PRIMARY","unitOfMeasure":"Participants"}